GlassScriptPhysician profile
Mark J Sarno
NPI 1861491144
$7,781.52
in general payments reported to CMS, 2019-2025
25 companies · $2,252 in 2025
The $2,252 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $685 · 2020: $266 · 2021: $811 · 2022: $607 · 2023: $890 · 2024: $2,271 · 2025: $2,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,283 · Entertainment: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,283.19 |
| Entertainment | $130.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,560.15 | 2021-2025 | Total30, Clareon, Hydrus Microstent |
| Bausch & Lomb Americas INC. | $1,476.84 | 2024-2025 | Xiidra, Miebo, Vyzulta |
| Coopervision INC. | $822.16 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens |
| Abbvie INC. | $404.52 | 2023-2024 | Xen Glaucoma Treatment System, Durysta |
| Sun Pharmaceutical Industries INC. | $387.82 | 2019-2021 | |
| Allergan, INC. | $367.32 | 2019-2022 | |
| Sight Sciences, INC. | $277.67 | 2024-2025 | Tearcare System, Omni Surgical System |
| Horizon Therapeutics Plc | $242.02 | 2022-2023 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $238.01 | 2024-2025 | Xdemvy |
| Amgen INC. | $218.67 | 2024-2025 | Tepezza |
| Oyster Point Pharma, INC. | $199.03 | 2022-2023 | Tyrvaya |
| Johnson & Johnson Surgical Vision, INC. | $195.25 | 2020-2023 | Lipiflow System Activator (Disposable) |
| Hoffmann-La Roche Limited | $133.01 | 2021 | |
| Optos, INC. | $130.17 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Ocular Therapeutix, INC. | $127.40 | 2024 | Dextenza |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $125.00 | 2021 | |
| Kala Pharmaceuticals, INC. | $121.95 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $120.48 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $114.75 | 2024 | Eylea Hd |
| Aerie Pharmaceuticals, INC. | $112.07 | 2019 | |
| Astellas Pharma US INC | $105.76 | 2024 | Izervay |
| Dompe US, INC. | $101.36 | 2024 | Oxervate |
| Lensar, INC. | $78.26 | 2020 | |
| Visionix USA, INC | $70.56 | 2022 | |
| Glaukos Corporation | $51.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Sarno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.